CA2891049C - Use of palmitoylethanolamide to delay onset of opioid tolerance - Google Patents

Use of palmitoylethanolamide to delay onset of opioid tolerance Download PDF

Info

Publication number
CA2891049C
CA2891049C CA2891049A CA2891049A CA2891049C CA 2891049 C CA2891049 C CA 2891049C CA 2891049 A CA2891049 A CA 2891049A CA 2891049 A CA2891049 A CA 2891049A CA 2891049 C CA2891049 C CA 2891049C
Authority
CA
Canada
Prior art keywords
palmitoylethanolamide
use according
opioid
micronized
pea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2891049A
Other languages
English (en)
French (fr)
Other versions
CA2891049A1 (en
Inventor
Francesco Della Valle
Maria Federica Della Valle
Lorenzo Di Cesare Manelli
Carla Ghelardini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epitech Group SpA
Original Assignee
Epitech Group SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitech Group SpA filed Critical Epitech Group SpA
Publication of CA2891049A1 publication Critical patent/CA2891049A1/en
Application granted granted Critical
Publication of CA2891049C publication Critical patent/CA2891049C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dispersion Chemistry (AREA)
CA2891049A 2014-05-14 2015-05-12 Use of palmitoylethanolamide to delay onset of opioid tolerance Active CA2891049C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2014A000876 2014-05-14
ITMI20140876 2014-05-14

Publications (2)

Publication Number Publication Date
CA2891049A1 CA2891049A1 (en) 2015-11-14
CA2891049C true CA2891049C (en) 2023-02-21

Family

ID=51179022

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2891049A Active CA2891049C (en) 2014-05-14 2015-05-12 Use of palmitoylethanolamide to delay onset of opioid tolerance

Country Status (17)

Country Link
US (1) US9801836B2 (https=)
EP (1) EP2944309B1 (https=)
JP (1) JP6563685B2 (https=)
KR (1) KR102507891B1 (https=)
CN (1) CN105079811B (https=)
AR (1) AR100444A1 (https=)
AU (1) AU2015202575B9 (https=)
BR (1) BR102015011079A2 (https=)
CA (1) CA2891049C (https=)
CY (1) CY1121773T1 (https=)
DK (1) DK2944309T3 (https=)
ES (1) ES2731729T3 (https=)
HU (1) HUE044915T2 (https=)
PL (1) PL2944309T3 (https=)
PT (1) PT2944309T (https=)
SM (1) SMT201900345T1 (https=)
TR (1) TR201908936T4 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42130A (fr) * 2015-05-21 2018-03-28 Therapix Biosciences Ltd Combinaisons d'opioïdes et de n-acyléthanolamines
PH12018000077B1 (en) 2017-07-05 2021-07-09 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
SG10201807034XA (en) 2017-09-05 2019-04-29 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease
WO2020141546A1 (en) 2019-01-02 2020-07-09 Celagenex Research (India) Pvt. Ltd. Synergistic nutritional compositions for pain management
EP4681710A1 (en) * 2024-07-18 2026-01-21 EPITECH GROUP S.p.A. 2-pentadecyl-2-oxazoline as an opioid adjuvant to prevent or treat hyperalgesia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1271266B (it) 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
WO2001010434A1 (en) 1999-08-06 2001-02-15 Innovet Italia S.R.L. Pharmaceutical compositions containing n-palmitoylethanolamide and use thereof in the veterinary field
DE60228713D1 (de) * 2001-07-18 2008-10-16 Unilever Nv Zusammensetzungen für die behandlung von haaren und/oder kopfhaut
US20050245557A1 (en) * 2003-10-15 2005-11-03 Pain Therapeutics, Inc. Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
MX2011010157A (es) * 2009-03-27 2011-10-11 Abbott Lab Compuestos utiles como ligandos del receptor canabinoide.
KR101662871B1 (ko) * 2009-09-07 2016-10-05 에피테크 그룹 에스.알.엘. 초미세화 팔미토일-에탄올아미드를 함유한 조성물

Also Published As

Publication number Publication date
CN105079811A (zh) 2015-11-25
TR201908936T4 (tr) 2019-07-22
AU2015202575B2 (en) 2020-03-05
CA2891049A1 (en) 2015-11-14
EP2944309B1 (en) 2019-03-20
ES2731729T3 (es) 2019-11-18
US20150328173A1 (en) 2015-11-19
BR102015011079A2 (pt) 2016-03-29
EP2944309A1 (en) 2015-11-18
SMT201900345T1 (it) 2019-07-11
US9801836B2 (en) 2017-10-31
PT2944309T (pt) 2019-06-05
KR20150130931A (ko) 2015-11-24
AU2015202575B9 (en) 2020-03-26
PL2944309T3 (pl) 2019-09-30
AU2015202575A1 (en) 2015-12-03
CY1121773T1 (el) 2020-07-31
KR102507891B1 (ko) 2023-03-08
CN105079811B (zh) 2020-06-23
JP2015221794A (ja) 2015-12-10
AR100444A1 (es) 2016-10-05
JP6563685B2 (ja) 2019-08-21
DK2944309T3 (da) 2019-06-03
HUE044915T2 (hu) 2019-11-28

Similar Documents

Publication Publication Date Title
JP6216305B2 (ja) 薬物過量摂取の治療のためのモルヒナン誘導体
US5256669A (en) Methods and compositions for treating acute or chronic pain and drug addiction
EP2964022B1 (en) Pain medicine combination and uses thereof
CA2891049C (en) Use of palmitoylethanolamide to delay onset of opioid tolerance
JPS6342605B2 (https=)
JP2014515405A (ja) オピオイド受容体アゴニストの逐次投与のための組成物
MX2012005538A (es) Combinacion de farmacos con teobromina y su uso en terapia.
KR20090125748A (ko) 대상포진 후 신경통 치료용 정제 및 대상포진 후 신경통의 치료 방법
WO2008075997A1 (en) Method for treating opioid withdrawal syndrome
WO2018052926A1 (en) Medicine combinations and treatment of restless leg syndrome
HK1217408B (en) Pain medicine combination and uses thereof
JPWO1997006139A1 (ja) 麻薬性鎮痛剤の依存・耐性形成抑制剤
HK1174496B (en) Morphinan derivatives for the treatment of drug overdose
HK1174496A (en) Morphinan derivatives for the treatment of drug overdose

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200403

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250429

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250429